

Regimen Reference Order – LEUK – gemtuzumab ozogamicin

ARIA: LEUK - [gemtuzumab ozogamicin]

Planned Course: Single course on Days 1, 4 and 7

Indication for Use: Acute Myeloid Leukemia Relapsed

CVAD: At Provider's Discretion

Proceed with treatment if:

- **AST/ALT is less than 2 times the upper limit of normal**
- **Total bilirubin is less than 2 times the upper limit of normal**

Proceed regardless of CBC

- ❖ **Contact Leukemia/BMT (L/BMT) Physician if parameters not met**

SEQUENCE OF MEDICATION ADMINISTRATION

Pre-treatment Requirements

Drug	Dose	CCMB Administration Guideline
Not Applicable		

Treatment Regimen – LEUK – gemtuzumab ozogamicin

Drug	Dose	CCMB Administration Guideline
Establish primary solution 500 mL of: normal saline		
Days 1, 4 and 7		
acetaminophen	650 mg	Orally 1 hour prior to gemtuzumab
diphenhydrAMINE	50 mg	IV in normal saline 50 mL over 15 minutes 1 hour prior to gemtuzumab <i>*Nursing Alert: gemtuzumab starts 1 hour after completion of diphenhydrAMINE infusion</i>
dexamethasone	12 mg	IV in normal saline 50 mL over 15 minutes 30 minutes prior to gemtuzumab
ondansetron	16 mg	Orally 30 minutes pre chemotherapy
gemtuzumab ozogamicin	3 mg/m ² Maximum dose is 4.5 mg	IV in normal saline 50 mL over 2 hours Use 0.2 or 0.22 micron filter <i>Concentration dependent drug: Pharmacy will adjust diluent volume to ensure drug stability</i>

Flush after each medication

- 50 mL over 6 minutes (500 mL/hr)

In the event of an infusion-related hypersensitivity reaction, refer to the 'Hypersensitivity Reaction Standing Order'

REQUIRED MONITORING

Prior to Days 1, 4 and 7, then weekly for 3 weeks

- CBC, biochemistry (including AST, ALT, bilirubin, alkaline phosphatase), type and screen as per Physician Orders
- Weight assessment by clinic

EKG monitoring

- At baseline within 1 week of starting therapy
- For patients with a history of or predisposition to QTc prolongation, or who are taking medicinal products known to prolong QTc or with relevant electrolyte disturbances, repeat EKG on Days 4 and 7 and then weekly for 3 weeks thereafter as indicated

gemtuzumab monitoring

- Full vital signs (temperature, heart rate, respiratory rate, blood pressure and O₂ saturation) at baseline and every 15 minutes
- If reaction occurs, monitor patient for at least 1 hour after completion of infusion. Patient can be discharged from treatment room if stable
- No observation period is required if no infusion-related reactions

Recommended Support Medications

Drug	Dose	CCMB Administration Guideline
Not Applicable		

DISCHARGE INSTRUCTIONS

- Patients should be instructed to contact their L/BMT physician immediately if symptoms of hypersensitivity reactions occur after discharge
- Reinforce applicable safe handling precautions of medications, blood and body fluids for 48 hours after completion of chemotherapy

ADDITIONAL INFORMATION

- QT prolongation has been associated with gemtuzumab ozogamicin